Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study

被引：0
|
作者：
Xiaoyang Zhai
Wanhu Li
Ji Li
Wenxiao Jia
Wang Jing
Yaru Tian
Shuhui Xu
Yuying Li
Hui Zhu
Jinming Yu
机构：
[1] Shantou University Medical College,Department of Radiation Oncology, Shandong Cancer Hospital and Institute
[2] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Radiology, Shandong Cancer Hospital and Institute
[3] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Oncology
[4] Renmin Hospital of Wuhan University,Department of Radiation Oncology
[5] Shandong Cancer Hospital and Institute Affiliated to Shandong University,undefined
[6] Shandong First Medical University,undefined
[7] Shandong Academy of Medical Sciences,undefined
来源：
Radiation Oncology | / 16卷
关键词：
Osimertinib; Cranial radiotherapy; Brain metastases; Leukoencephalopathy; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
    Planchard, D.
    Toffart, A. C.
    Flandin, A-C. Madroszyk
    Wislez, M.
    Martinez, S.
    Monnet, I.
    Hiret, S.
    Gounant, V.
    Metivier, A-C.
    Domblides, C.
    Giroux-Leprieur, E.
    Huchot, E.
    Tomasini, P.
    Mascaux, C.
    Carmier, D.
    Langlais, A.
    Morin, F.
    Westeel, V.
    Cortot, A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [32] An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
    Ekman, S.
    Varrone, A.
    Jucaite, A.
    Vishwanathan, K.
    Brown, A.
    Cselenyi, Z.
    Martin, H.
    Lewensohn, R.
    Schou, M.
    Laus, G.
    Van Der Aart, J.
    Johnstrom, P.
    Singh, N.
    Farde, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S842 - S842
  • [33] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [34] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
  • [35] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [36] Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study
    Zhou, Bin
    Gong, Qiang
    Li, Ben
    Qie, Hai-Ling
    Li, Wei
    Jiang, Hong-Tao
    Li, He-Fei
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (05) : 643 - 651
  • [37] High-dose aumolertinib versus osimertinib in EGFR T790M+NSCLC patients with brain metastases (ATTACK)
    Lu, S.
    Han, L.
    Lv, D.
    Zhang, Z.
    Wu, J.
    Wang, Q.
    Dong, X.
    Hu, Y.
    Chen, J.
    Wu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S86 - S86
  • [38] Different Efficacy of Osimertinib for EGFR Exon 19del or L858R in NSCLC Patients with Brain Metastases
    Li, X.
    Li, B.
    Zhang, D.
    Zou, B.
    Wang, R. Z.
    Yu, J.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E143 - E143
  • [39] The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study
    Zhu, L.
    Zhang, S.
    Xia, B.
    Chen, X.
    Ma, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1910 - S1910
  • [40] MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases
    Tang, X.
    Li, Y.
    Qian, W. -L.
    Han, P. -L.
    Yan, W. -F.
    Yang, Z. -G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S349 - S349
12345